Gradientech’s Nomination Committee for the 2023 Annual General Meeting

The Nomination Committee for Gradientech AB prior to the 2023 Annual General Meeting has been appointed based on the ownership structure as of August 31, 2022.

The Nomination Committee consists of:

• Henrik Didner, representing Monesi Förvaltnings AB
• Allan Asp, representing Almi funds
• Andy Browning, nominated by Sara Thorslund and Johan Kreuger
• Mikael Lönn

The shareholders who have appointed members to the Nomination Committee together represent approximately 26 percent of the voting rights for all shares in Gradientech AB.

The annual general meeting in Gradientech AB will be held on Wednesday May 10, 2023. Shareholders who wish to submit proposals to the Nomination Committee can do so via e-mail to ir@gradientech.se or by letter to:

Gradientech AB
Uppsala Science Park
SE-751 83 Uppsala

In order for proposals to be processed by the Nomination Committee, they should be received by 31 January 2023 at the latest.

For more information please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se

About Gradientech*
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.